| The Mobile Element Locator Tool (MELT): population-scale mobile element discovery and biology EJ Gardner, VK Lam, DN Harris, NT Chuang, EC Scott, WS Pittard, ... Genome research 27 (11), 1916-1929, 2017 | 324 | 2017 |
| Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer J Nong, Y Gong, Y Guan, X Yi, Y Yi, L Chang, L Yang, J Lv, Z Guo, H Jia, ... Nature communications 9 (1), 3114, 2018 | 143 | 2018 |
| Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer J Yang, Y Gong, VK Lam, Y Shi, Y Guan, Y Zhang, L Ji, Y Chen, Y Zhao, ... Cell death & disease 11 (5), 346, 2020 | 127 | 2020 |
| Neutrophil‐lymphocyte ratio is a prognostic marker in patients with locally advanced (Stage IIIA and IIIB) non‐small cell lung cancer treated with combined modality therapy KA Scilla, SM Bentzen, VK Lam, P Mohindra, EM Nichols, MA Vyfhuis, ... The oncologist 22 (6), 737-742, 2017 | 106 | 2017 |
| PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non–small … MV Negrao, VK Lam, A Reuben, ML Rubin, LL Landry, EB Roarty, ... Journal of Thoracic Oncology 14 (6), 1021-1031, 2019 | 88 | 2019 |
| Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC) VK Lam, SM Bentzen, P Mohindra, EM Nichols, N Bhooshan, M Vyfhuis, ... Lung Cancer 104, 52-57, 2017 | 73 | 2017 |
| Poziotinib for patients with HER2 exon 20 mutant non–small-cell lung cancer: Results from a phase II trial YY Elamin, JP Robichaux, BW Carter, M Altan, DL Gibbons, FV Fossella, ... Journal of Clinical Oncology 40 (7), 702, 2022 | 70 | 2022 |
| Persistent mutation burden drives sustained anti-tumor immune responses N Niknafs, A Balan, C Cherry, K Hummelink, K Monkhorst, XM Shao, ... Nature medicine 29 (2), 440-449, 2023 | 49 | 2023 |
| Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity YY Elamin, JP Robichaux, BW Carter, M Altan, H Tran, DL Gibbons, ... Cancer Cell 40 (7), 754-767. e6, 2022 | 49 | 2022 |
| Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC VK Lam, J Zhang, CC Wu, HT Tran, L Li, L Diao, J Wang, ... Journal of Thoracic Oncology 16 (4), 601-609, 2021 | 47 | 2021 |
| High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer E Massarelli, VK Lam, ER Parra, J Rodriguez-Canales, C Behrens, L Diao, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 46 | 2019 |
| Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy M Hwang, JV Canzoniero, S Rosner, G Zhang, JR White, Z Belcaid, ... Journal for immunotherapy of cancer 10 (6), 2022 | 44 | 2022 |
| Targeted tissue and cell-free tumor DNA sequencing of advanced lung squamous-cell carcinoma reveals clinically significant prevalence of actionable alterations VK Lam, HT Tran, KC Banks, RB Lanman, W Rinsurongkawong, N Peled, ... Clinical lung cancer 20 (1), 30-36. e3, 2019 | 44 | 2019 |
| Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens B Hannigan, W Ye, M Mehrotra, V Lam, A Bolivar, S Zalles, BA Barkoh, ... Annals of Oncology 30 (6), 963-969, 2019 | 36 | 2019 |
| Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy L Sivapalan, JC Murray, JVL Canzoniero, B Landon, J Jackson, S Scott, ... Journal for immunotherapy of cancer 11 (1), 2023 | 33 | 2023 |
| Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy C Friedes, T Chakrabarti, S Olson, L Prichett, JR Brahmer, PM Forde, ... Lung Cancer 154, 36-43, 2021 | 33 | 2021 |
| A phase I/II study of neoadjuvant cisplatin, docetaxel, and nintedanib for resectable non–small cell lung cancer T Cascone, B Sepesi, HY Lin, N Kalhor, ER Parra, M Jiang, MCB Godoy, ... Clinical Cancer Research 26 (14), 3525-3536, 2020 | 25 | 2020 |
| Master protocols in lung cancer: experience from Lung Master Protocol VK Lam, V Papadimitrakopoulou Current opinion in oncology 30 (2), 92-97, 2018 | 23 | 2018 |
| Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer GR Blumenschein, S Devarakonda, M Johnson, V Moreno, J Gainor, ... Journal for immunotherapy of cancer 10 (1), 2022 | 21 | 2022 |
| Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer VK Lam, J Zhang Journal of Thoracic Disease 11 (6), 2208, 2019 | 16 | 2019 |
